Can This Beaten-Down Stock Bounce Back in 2025?
In 2022, pharmaceutical giant (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price. Pfizer has made progress, especially on the clinical and regulatory fronts, through acquisitions and internally developed programs. But nothing has stopped the bleeding -- yet.
Could 2025 be different? Let's see whether the drugmaker can finally turn things around this year.
Pfizer's woes started because it couldn't keep delivering the kinds of financial results it did during the earlier pandemic years, or even anything close to that. If the drugmaker can at least consistently grow its revenue and earnings at a good clip, that might lead more investors to buy the stock at current levels.
Source Fool.com
Pfizer Inc. Stock
We see a rather positive sentiment for Pfizer Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 27 € shows a positive potential of 20.13% compared to the current price of 22.48 € for Pfizer Inc..
